{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T04:12:28Z","timestamp":1782187948727,"version":"3.54.5"},"reference-count":97,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,4,26]],"date-time":"2023-04-26T00:00:00Z","timestamp":1682467200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,4,26]],"date-time":"2023-04-26T00:00:00Z","timestamp":1682467200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Healthier Lives National Science Challenge, NZ"},{"name":"Cancer Research Trust, NZ"},{"DOI":"10.13039\/501100018883","name":"Maurice Wilkins Centre for Molecular Biodiscovery","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100018883","id-type":"DOI","asserted-by":"publisher"}]},{"name":"William Staunton Scholarship Fund"},{"name":"University of Auckland School of Medicine Foundation"},{"DOI":"10.13039\/501100001537","name":"University of Auckland","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001537","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Diagn Ther"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1007\/s40291-023-00651-4","type":"journal-article","created":{"date-parts":[[2023,4,26]],"date-time":"2023-04-26T06:02:26Z","timestamp":1682488946000},"page":"537-550","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Dynamic ctDNA Mutational Complexity in Patients with Melanoma Receiving Immunotherapy"],"prefix":"10.1007","volume":"27","author":[{"given":"Sandra","family":"Fitzgerald","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cherie","family":"Blenkiron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosalie","family":"Stephens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon A.","family":"Mathy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiffany","family":"Somers-Edgar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gill","family":"Rolfe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Eccles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamsin","family":"Robb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Euan","family":"Rodger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"Lawrence","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parry","family":"Guilford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette","family":"Lasham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8345-7812","authenticated-orcid":false,"given":"Cristin G.","family":"Print","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,26]]},"reference":[{"issue":"7","key":"651_CR1","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1016\/j.cell.2015.05.044","volume":"161","author":"R Akbani","year":"2015","unstructured":"Akbani R, et\u00a0al. Genomic classification of cutaneous melanoma. Cell. 2015;161(7):1681\u201396.","journal-title":"Cell"},{"issue":"5","key":"651_CR2","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1038\/ng.3275","volume":"47","author":"MB Mann","year":"2015","unstructured":"Mann MB, et\u00a0al. Transposon mutagenesis identifies genetic drivers of Braf(V600E) melanoma. Nat Genet. 2015;47(5):486\u201395.","journal-title":"Nat Genet"},{"key":"651_CR3","doi-asserted-by":"publisher","first-page":"184","DOI":"10.3389\/fonc.2013.00184","volume":"3","author":"A Trevarton","year":"2013","unstructured":"Trevarton A, et\u00a0al. MelanomaDB: A web tool for integrative analysis of melanoma genomic information to identify disease-associated molecular pathways. Front Oncol. 2013;3:184.","journal-title":"Front Oncol"},{"key":"651_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2020.103187","volume":"157","author":"S Gandini","year":"2021","unstructured":"Gandini S, et\u00a0al. Circulating tumour DNA and melanoma survival: A systematic literature review and meta-analysis. Crit Rev Oncol Hematol. 2021;157: 103187.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"6","key":"651_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2021.101072","volume":"14","author":"SN Feng","year":"2021","unstructured":"Feng SN, et\u00a0al. The prognostic value of circulating tumor DNA in patients with melanoma: A systematic review and meta-analysis. Transl Oncol. 2021;14(6): 101072.","journal-title":"Transl Oncol"},{"key":"651_CR6","doi-asserted-by":"crossref","unstructured":"Gray, E.S., et\u00a0al., Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma. Oncotarget, 2015. 6.","DOI":"10.18632\/oncotarget.5788"},{"issue":"3","key":"651_CR7","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1158\/1078-0432.CCR-15-0321","volume":"22","author":"A Santiago-Walker","year":"2016","unstructured":"Santiago-Walker A, et\u00a0al. Correlation of BRAF mutation status in circulating-free DNA and tumor and association with clinical outcome across four BRAFi and MEKi clinical trials. Clin Cancer Res. 2016;22(3):567\u201374.","journal-title":"Clin Cancer Res"},{"issue":"26","key":"651_CR8","doi-asserted-by":"publisher","first-page":"3205","DOI":"10.1200\/JCO.2013.49.8691","volume":"31","author":"PA Ascierto","year":"2013","unstructured":"Ascierto PA, et\u00a0al. Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma. J Clin Oncol. 2013;31(26):3205\u201311.","journal-title":"J Clin Oncol"},{"issue":"5","key":"651_CR9","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1093\/annonc\/mdx026","volume":"28","author":"JH Lee","year":"2017","unstructured":"Lee JH, et\u00a0al. Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanoma. Ann Oncol. 2017;28(5):1130\u20136.","journal-title":"Ann Oncol"},{"issue":"2","key":"651_CR10","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.cell.2020.09.001","volume":"183","author":"BY Nabet","year":"2020","unstructured":"Nabet BY, et\u00a0al. Noninvasive early identification of therapeutic benefit from immune checkpoint inhibition. Cell. 2020;183(2):363-376.e13.","journal-title":"Cell"},{"key":"651_CR11","doi-asserted-by":"publisher","DOI":"10.1200\/PO.21.00372","volume":"6","author":"DM Vega","year":"2022","unstructured":"Vega DM, et\u00a0al. Changes in circulating tumor DNA reflect clinical benefit across multiple studies of patients with non\u2013small-cell lung cancer treated with immune checkpoint inhibitors. JCO Precis Oncol. 2022;6: e2100372.","journal-title":"JCO Precis Oncol"},{"issue":"22","key":"651_CR12","doi-asserted-by":"publisher","first-page":"5480","DOI":"10.1158\/1078-0432.CCR-16-0613","volume":"22","author":"L Xi","year":"2016","unstructured":"Xi L, et\u00a0al. Circulating tumor DNA as an early indicator of response to T-cell transfer immunotherapy in metastatic melanoma. Clin Cancer Res. 2016;22(22):5480\u20136.","journal-title":"Clin Cancer Res"},{"key":"651_CR13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.16.00009","volume":"1","author":"SQ Wong","year":"2017","unstructured":"Wong SQ, et\u00a0al. Circulating tumor DNA analysis and functional imaging provide complementary approaches for comprehensive disease monitoring in metastatic melanoma. JCO Precis Oncol. 2017;1:1\u201314.","journal-title":"JCO Precis Oncol"},{"key":"651_CR14","doi-asserted-by":"publisher","first-page":"11198","DOI":"10.1038\/srep11198","volume":"5","author":"S Chang-Hao Tsao","year":"2015","unstructured":"Chang-Hao Tsao S, et\u00a0al. Monitoring response to therapy in melanoma by quantifying circulating tumour DNA with droplet digital PCR for BRAF and NRAS mutations. Sci Rep. 2015;5:11198.","journal-title":"Sci Rep"},{"issue":"5","key":"651_CR15","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1373\/clinchem.2017.281543","volume":"64","author":"V Haselmann","year":"2018","unstructured":"Haselmann V, et\u00a0al. Liquid profiling of circulating tumor DNA in plasma of melanoma patients for companion diagnostics and monitoring of BRAF inhibitor therapy. Clin Chem. 2018;64(5):830\u201342.","journal-title":"Clin Chem"},{"key":"651_CR16","doi-asserted-by":"crossref","unstructured":"Marsavela, G., et\u00a0al., Detection of clinical progression through plasma ctDNA in metastatic melanoma patients: a comparison to radiological progression. British Journal of Cancer, 2021.","DOI":"10.1038\/s41416-021-01507-6"},{"issue":"11","key":"651_CR17","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1093\/carcin\/bgaa102","volume":"41","author":"D Zou","year":"2020","unstructured":"Zou D, et\u00a0al. Circulating tumor DNA is a sensitive marker for routine monitoring of treatment response in advanced colorectal cancer. Carcinogenesis. 2020;41(11):1507\u201317.","journal-title":"Carcinogenesis"},{"issue":"8","key":"651_CR18","doi-asserted-by":"publisher","first-page":"1996","DOI":"10.1093\/annonc\/mdx212","volume":"28","author":"L Cabel","year":"2017","unstructured":"Cabel L, et\u00a0al. Circulating tumor DNA changes for early monitoring of anti-PD1 immunotherapy: a proof-of-concept study. Ann Oncol. 2017;28(8):1996\u20132001.","journal-title":"Ann Oncol"},{"key":"651_CR19","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s12967-016-0852-6","volume":"14","author":"M Schreuer","year":"2016","unstructured":"Schreuer M, et\u00a0al. Quantitative assessment of BRAF V600 mutant circulating cell-free tumor DNA as a tool for therapeutic monitoring in metastatic melanoma patients treated with BRAF\/MEK inhibitors. J Transl Med. 2016;14:95\u201395.","journal-title":"J Transl Med"},{"issue":"10","key":"651_CR20","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1002\/1878-0261.12373","volume":"12","author":"SP Rowe","year":"2018","unstructured":"Rowe SP, et\u00a0al. From validity to clinical utility: the influence of circulating tumor DNA on melanoma patient management in a real-world setting. Mol Oncol. 2018;12(10):1661\u201372.","journal-title":"Mol Oncol"},{"issue":"1","key":"651_CR21","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s40425-014-0042-0","volume":"2","author":"EJ Lipson","year":"2014","unstructured":"Lipson EJ, et\u00a0al. Circulating tumor DNA analysis as a real-time method for monitoring tumor burden in melanoma patients undergoing treatment with immune checkpoint blockade. J Immunother Cancer. 2014;2(1):42.","journal-title":"J Immunother Cancer"},{"key":"651_CR22","doi-asserted-by":"crossref","unstructured":"V\u00e1raljai, R., et\u00a0al., Application of circulating cell-free tumor DNA profiles for therapeutic monitoring and outcome prediction in genetically heterogeneous metastatic melanoma. JCO Precis Oncol. 2020. 3.","DOI":"10.1200\/PO.18.00229"},{"issue":"3","key":"651_CR23","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1007\/s40291-021-00528-4","volume":"25","author":"MW Linder","year":"2021","unstructured":"Linder MW, et\u00a0al. Longitudinal relationship between idylla plasma ctBRAF V600 mutation detection and tumor burden in patients with metastatic melanoma. Mol Diagn Ther. 2021;25(3):361\u201371.","journal-title":"Mol Diagn Ther"},{"issue":"1","key":"651_CR24","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1186\/s12967-019-2051-8","volume":"17","author":"T Seremet","year":"2019","unstructured":"Seremet T, et\u00a0al. Undetectable circulating tumor DNA (ctDNA) levels correlate with favorable outcome in metastatic melanoma patients treated with anti-PD1 therapy. J Transl Med. 2019;17(1):303.","journal-title":"J Transl Med"},{"issue":"22","key":"651_CR25","doi-asserted-by":"publisher","first-page":"8604","DOI":"10.1021\/ac202028g","volume":"83","author":"BJ Hindson","year":"2011","unstructured":"Hindson BJ, et\u00a0al. High-throughput droplet digital PCR system for absolute quantitation of DNA copy number. Anal Chem. 2011;83(22):8604\u201310.","journal-title":"Anal Chem"},{"issue":"1","key":"651_CR26","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1373\/clinchem.2014.230235","volume":"61","author":"MF Sanmamed","year":"2015","unstructured":"Sanmamed MF, et\u00a0al. Quantitative cell-free circulating BRAFV600E mutation analysis by use of droplet digital PCR in the follow-up of patients with melanoma being treated with BRAF inhibitors. Clin Chem. 2015;61(1):297\u2013304.","journal-title":"Clin Chem"},{"issue":"1","key":"651_CR27","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1097\/CMR.0000000000000415","volume":"28","author":"T Seremet","year":"2018","unstructured":"Seremet T, et\u00a0al. Illustrative cases for monitoring by quantitative analysis of BRAF\/NRAS ctDNA mutations in liquid biopsies of metastatic melanoma patients who gained clinical benefits from anti-PD1 antibody therapy. Melanoma Res. 2018;28(1):65\u201370.","journal-title":"Melanoma Res"},{"key":"651_CR28","doi-asserted-by":"crossref","unstructured":"Kim, M.K., et\u00a0al. Prognostic Implications of Multiplex Detection of KRAS Mutations in Cell-Free DNA from Patients with Pancreatic Ductal Adenocarcinoma. Clin Chem. 2018.","DOI":"10.1373\/clinchem.2017.283721"},{"key":"651_CR29","unstructured":"Bettegowda, C., et\u00a0al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med. 2014. 6."},{"key":"651_CR30","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/s41525-017-0030-7","volume":"2","author":"A Cutts","year":"2017","unstructured":"Cutts A, et\u00a0al. Characterisation of the changing genomic landscape of metastatic melanoma using cell free DNA. NPJ Genom Med. 2017;2:25.","journal-title":"NPJ Genom Med"},{"issue":"10","key":"651_CR31","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1093\/annonc\/mdu288","volume":"25","author":"F Rothe","year":"2014","unstructured":"Rothe F, et\u00a0al. Plasma circulating tumor DNA as an alternative to metastatic biopsies for mutational analysis in breast cancer. Ann Oncol. 2014;25(10):1959\u201365.","journal-title":"Ann Oncol"},{"key":"651_CR32","doi-asserted-by":"crossref","unstructured":"Phallen, J., et\u00a0al. Direct detection of early-stage cancers using circulating tumor DNA. Sci Transl Med. 2017. 9(403).","DOI":"10.1126\/scitranslmed.aan2415"},{"issue":"1","key":"651_CR33","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1038\/s41467-017-00965-y","volume":"8","author":"VA Adalsteinsson","year":"2017","unstructured":"Adalsteinsson VA, et\u00a0al. Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors. Nat Commun. 2017;8(1):1324.","journal-title":"Nat Commun"},{"issue":"5","key":"651_CR34","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/nrg.2017.117","volume":"19","author":"JJ Salk","year":"2018","unstructured":"Salk JJ, Schmitt MW, Loeb LA. Enhancing the accuracy of next-generation sequencing for detecting rare and subclonal mutations. Nat Rev Genet. 2018;19(5):269\u201385.","journal-title":"Nat Rev Genet"},{"issue":"10","key":"651_CR35","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1111\/1759-7714.13154","volume":"10","author":"PN Ding","year":"2019","unstructured":"Ding PN, et\u00a0al. Plasma next generation sequencing and droplet digital PCR-based detection of epidermal growth factor receptor (EGFR) mutations in patients with advanced lung cancer treated with subsequent-line osimertinib. Thorac Cancer. 2019;10(10):1879\u201384.","journal-title":"Thorac Cancer"},{"key":"651_CR36","doi-asserted-by":"crossref","unstructured":"Bingham, M. et\u00a0al. 692P Identification of an RNF43 mutated gastric cancer patient population with potential sensitivity to porcupine inhibitor RXC004 and development of a complimentary ctDNA liquid biopsy assay for patient screening. Ann Oncol. 2017. 28(suppl_5): p. mdx369.076-mdx369.076.","DOI":"10.1093\/annonc\/mdx369.076"},{"key":"651_CR37","doi-asserted-by":"crossref","unstructured":"Saffroy, R. et\u00a0al. Ultra-sensitive mass spectrometry allows 33% increased detection of somatic EGFR T790M mutation in plasma cfDNA samples. Ann Oncol. 2016. 27(suppl_6): p. 62P-62P.","DOI":"10.1093\/annonc\/mdw363.11"},{"issue":"1","key":"651_CR38","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.jmoldx.2015.08.001","volume":"18","author":"MJ Mosko","year":"2016","unstructured":"Mosko MJ, et\u00a0al. Ultrasensitive detection of multiplexed somatic mutations using MALDI-TOF mass spectrometry. J Mol Diagn. 2016;18(1):23\u201331.","journal-title":"J Mol Diagn"},{"key":"651_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejca.2017.10.029","volume":"88","author":"S Valpione","year":"2017","unstructured":"Valpione S, et\u00a0al. Plasma total cell-free DNA (cfDNA) is a surrogate biomarker for tumour burden and a prognostic biomarker for survival in metastatic melanoma patients. Eur J Cancer. 2017;88:1\u20139.","journal-title":"Eur J Cancer"},{"issue":"10","key":"651_CR40","doi-asserted-by":"publisher","first-page":"2471","DOI":"10.1158\/1078-0432.CCR-16-1691","volume":"23","author":"S Parpart-Li","year":"2017","unstructured":"Parpart-Li S, et\u00a0al. The effect of preservative and temperature on the analysis of circulating tumor DNA. Clin Cancer Res. 2017;23(10):2471\u20137.","journal-title":"Clin Cancer Res"},{"key":"651_CR41","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.ab.2017.11.004","volume":"542","author":"S Nikolaev","year":"2018","unstructured":"Nikolaev S, et\u00a0al. Circulating tumoral DNA: Preanalytical validation and quality control in a diagnostic laboratory. Anal Biochem. 2018;542:34\u20139.","journal-title":"Anal Biochem"},{"issue":"4","key":"651_CR42","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/j.molonc.2015.11.006","volume":"10","author":"DG Rothwell","year":"2016","unstructured":"Rothwell DG, et\u00a0al. Genetic profiling of tumours using both circulating free DNA and circulating tumour cells isolated from the same preserved whole blood sample. Mol Oncol. 2016;10(4):566\u201374.","journal-title":"Mol Oncol"},{"issue":"3","key":"651_CR43","doi-asserted-by":"publisher","first-page":"704","DOI":"10.3390\/ijms20030704","volume":"20","author":"A Ward Gahlawat","year":"2019","unstructured":"Ward Gahlawat A, et\u00a0al. Evaluation of storage tubes for combined analysis of circulating nucleic acids in liquid biopsies. Int J Mol Sci. 2019;20(3):704.","journal-title":"Int J Mol Sci"},{"issue":"18","key":"651_CR44","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1016\/j.clinbiochem.2016.03.012","volume":"49","author":"Q Kang","year":"2016","unstructured":"Kang Q, et\u00a0al. Comparative analysis of circulating tumor DNA stability in K3EDTA, Streck, and Cell Save blood collection tubes. Clin Biochem. 2016;49(18):1354\u201360.","journal-title":"Clin Biochem"},{"issue":"2","key":"651_CR45","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.healthpol.2014.05.002","volume":"118","author":"G Nixon","year":"2014","unstructured":"Nixon G, et\u00a0al. Geographic disparities in the utilisation of computed tomography scanning services in southern New Zealand. Health Policy. 2014;118(2):222\u20138.","journal-title":"Health Policy"},{"issue":"1493","key":"651_CR46","first-page":"6","volume":"132","author":"D Sarfati","year":"2019","unstructured":"Sarfati D, et\u00a0al. Cancer Care at a Crossroads: time to make a choice. N Z Med J. 2019;132(1493):6\u201311.","journal-title":"N Z Med J"},{"key":"651_CR47","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1200\/GO.20.00028","volume":"6","author":"J Gurney","year":"2020","unstructured":"Gurney J, et\u00a0al. Disparities in cancer-specific survival between M\u0101ori and non-M\u0101ori New Zealanders, 2007\u20132016. JCO Global Oncology. 2020;6:766\u201374.","journal-title":"JCO Global Oncology"},{"issue":"7","key":"651_CR48","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1007\/s10552-012-9986-x","volume":"23","author":"I Meredith","year":"2012","unstructured":"Meredith I, et\u00a0al. Cancer in Pacific people in New Zealand. Cancer Causes Control. 2012;23(7):1173\u201384.","journal-title":"Cancer Causes Control"},{"key":"651_CR49","unstructured":"Health and Disability System Review Final Report \u2013 P\u016brongo Whakamutunga. www.systemreview.health.govt.nz\/final-report 2020."},{"issue":"5","key":"651_CR50","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1001\/jamadermatol.2022.0160","volume":"158","author":"M Arnold","year":"2022","unstructured":"Arnold M, et\u00a0al. Global burden of cutaneous melanoma in 2020 and projections to 2040. JAMA Dermatol. 2022;158(5):495\u2013503.","journal-title":"JAMA Dermatol"},{"issue":"3","key":"651_CR51","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, et\u00a0al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"6","key":"651_CR52","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1158\/1055-9965.EPI-08-0682","volume":"18","author":"MJ Sneyd","year":"2009","unstructured":"Sneyd MJ, Cox B. Melanoma in Maori, Asian, and Pacific peoples in New Zealand. Cancer Epidemiol Biomarkers Prev. 2009;18(6):1706\u201313.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"2","key":"651_CR53","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/s41416-020-01038-6","volume":"124","author":"VA Zavala","year":"2021","unstructured":"Zavala VA, et\u00a0al. Cancer health disparities in racial\/ethnic minorities in the United States. Br J Cancer. 2021;124(2):315\u201332.","journal-title":"Br J Cancer"},{"issue":"1","key":"651_CR54","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1186\/1471-2407-14-517","volume":"14","author":"SP Moore","year":"2014","unstructured":"Moore SP, et\u00a0al. Survival disparities in Australia: an analysis of patterns of care and comorbidities among indigenous and non-indigenous cancer patients. BMC Cancer. 2014;14(1):517.","journal-title":"BMC Cancer"},{"key":"651_CR55","doi-asserted-by":"crossref","unstructured":"Eisenhauer, E.A. et\u00a0al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009. 45(2): p. 228-47.","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"651_CR56","doi-asserted-by":"crossref","unstructured":"Rizvi, N.A. et\u00a0al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015. 348(6230): p. 124-8.","DOI":"10.1126\/science.aaa1348"},{"issue":"21","key":"651_CR57","doi-asserted-by":"publisher","first-page":"e31","DOI":"10.1158\/0008-5472.CAN-17-0337","volume":"77","author":"JT Robinson","year":"2017","unstructured":"Robinson JT, et\u00a0al. Variant review with the Integrative Genomics Viewer. Cancer Res. 2017;77(21):e31\u20134.","journal-title":"Cancer Res"},{"key":"651_CR58","unstructured":"https:\/\/www.agenabio.com\/wp-content\/uploads\/2021\/12\/Agena-Bioscience-UltraSEEK-V2-Melanoma-Variant-List-ONC005201.pdf."},{"issue":"4","key":"651_CR59","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1373\/clinchem.2017.284257","volume":"64","author":"AJ Colebatch","year":"2018","unstructured":"Colebatch AJ, et\u00a0al. Optimizing amplification of the GC-rich TERT promoter region using 7-Deaza-dGTP for droplet digital PCR quantification of TERT promoter mutations. Clin Chem. 2018;64(4):745\u20137.","journal-title":"Clin Chem"},{"key":"651_CR60","unstructured":"The R Project for Statistical Computing. https:\/\/www.R-project.org 2022."},{"key":"651_CR61","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/978-3-319-24277-4_9","volume-title":"ggplot2","author":"H Wickham","year":"2016","unstructured":"Wickham H. Data analysis. In: ggplot2. Springer; 2016. p. 189\u2013201."},{"key":"651_CR62","unstructured":"Therneau, T., A Package for Survival Analysis in R. R package version 3.3-1. https:\/\/CRAN.R-project.org\/package=survival 2022."},{"key":"651_CR63","unstructured":"Wilke, C., Cowplot: Streamlined Plot Theme and Plot Annotations for 'ggplot2'. https:\/\/cloud.r-project.org\/web\/packages\/cowplot\/index.html, 2020. R package version 1.1.1."},{"key":"651_CR64","doi-asserted-by":"crossref","unstructured":"Kassambara, A.K., M, survminer: Drawing Survival Curves using 'ggplot2. https:\/\/CRAN.R-project.org\/package=survminer 2016. R package version 0.2.4.","DOI":"10.32614\/CRAN.package.survminer"},{"issue":"15","key":"651_CR65","doi-asserted-by":"publisher","first-page":"4064","DOI":"10.1158\/1078-0432.CCR-19-3926","volume":"26","author":"JH Lee","year":"2020","unstructured":"Lee JH, et\u00a0al. Longitudinal monitoring of ctDNA in patients with melanoma and brain metastases treated with immune checkpoint inhibitors. Clin Cancer Res. 2020;26(15):4064\u201371.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"651_CR66","doi-asserted-by":"publisher","first-page":"3199","DOI":"10.1038\/s41467-021-23394-4","volume":"12","author":"B Pereira","year":"2021","unstructured":"Pereira B, et\u00a0al. Cell-free DNA captures tumor heterogeneity and driver alterations in rapid autopsies with pre-treated metastatic cancer. Nat Commun. 2021;12(1):3199.","journal-title":"Nat Commun"},{"issue":"1","key":"651_CR67","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1158\/2767-9764.CRC-22-0101","volume":"3","author":"TJ Robb","year":"2023","unstructured":"Robb TJ, et\u00a0al. Complex patterns of genomic heterogeneity identified in 42 tumor samples and ctDNA of a pulmonary atypical carcinoid patient. Cancer Res Commun. 2023;3(1):31\u201342.","journal-title":"Cancer Res Commun"},{"issue":"1","key":"651_CR68","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1186\/s12885-018-4637-6","volume":"18","author":"AC McEvoy","year":"2018","unstructured":"McEvoy AC, et\u00a0al. Correlation between circulating tumour DNA and metabolic tumour burden in metastatic melanoma patients. BMC Cancer. 2018;18(1):726.","journal-title":"BMC Cancer"},{"issue":"8","key":"651_CR69","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.1158\/1078-0432.CCR-17-1341","volume":"24","author":"SB Goldberg","year":"2018","unstructured":"Goldberg SB, et\u00a0al. Early assessment of lung cancer immunotherapy response via circulating tumor DNA. Clin Cancer Res. 2018;24(8):1872\u201380.","journal-title":"Clin Cancer Res"},{"issue":"11","key":"651_CR70","doi-asserted-by":"publisher","first-page":"4748","DOI":"10.1111\/cas.15088","volume":"112","author":"E Takai","year":"2021","unstructured":"Takai E, et\u00a0al. Clonal dynamics of circulating tumor DNA during immune checkpoint blockade therapy for melanoma. Cancer Sci. 2021;112(11):4748\u201357.","journal-title":"Cancer Sci"},{"issue":"8","key":"651_CR71","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.3390\/cancers13081826","volume":"13","author":"G Herbreteau","year":"2021","unstructured":"Herbreteau G, et\u00a0al. Circulating tumor DNA early kinetics predict response of metastatic melanoma to anti-PD1 immunotherapy: Validation study. Cancers. 2021;13(8):1826.","journal-title":"Cancers"},{"key":"651_CR72","doi-asserted-by":"crossref","unstructured":"Bratman, S.V. et\u00a0al. Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab. Nature Cancer. 2020.","DOI":"10.1038\/s43018-020-0096-5"},{"key":"651_CR73","doi-asserted-by":"crossref","unstructured":"Lampignano, R. et\u00a0al. Multicenter Evaluation of Circulating Cell-Free DNA Extraction and Downstream Analyses for the Development of Standardized (Pre)analytical Work Flows. Clin Chem. 2019.","DOI":"10.1373\/clinchem.2019.306837"},{"issue":"3","key":"651_CR74","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1093\/annonc\/mdy552","volume":"30","author":"C Abbosh","year":"2019","unstructured":"Abbosh C, Swanton C, Birkbak NJ. Clonal haematopoiesis: a source of biological noise in cell-free DNA analyses. Ann Oncol. 2019;30(3):358\u20139.","journal-title":"Ann Oncol"},{"issue":"22","key":"651_CR75","doi-asserted-by":"publisher","first-page":"3404","DOI":"10.1182\/bloodadvances.2018020222","volume":"2","author":"DP Steensma","year":"2018","unstructured":"Steensma DP. Clinical consequences of clonal hematopoiesis of indeterminate potential. Blood Adv. 2018;2(22):3404\u201310.","journal-title":"Blood Adv"},{"issue":"18","key":"651_CR76","first-page":"4437","volume":"24","author":"Y Hu","year":"2018","unstructured":"Hu Y, et\u00a0al. False-positive plasma genotyping due to clonal hematopoiesis. 2018;24(18):4437\u201343.","journal-title":"False-positive plasma genotyping due to clonal hematopoiesis"},{"key":"651_CR77","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.clinbiochem.2021.03.005","volume":"92","author":"F Huang","year":"2021","unstructured":"Huang F, et\u00a0al. Chemotherapy-associated clonal hematopoiesis mutations should be taken seriously in plasma cell-free DNA KRAS\/NRAS\/BRAF genotyping for metastatic colorectal cancer. Clin Biochem. 2021;92:46\u201353.","journal-title":"Clin Biochem"},{"issue":"2","key":"651_CR78","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/s41416-020-01047-5","volume":"124","author":"L Keller","year":"2021","unstructured":"Keller L, et\u00a0al. Clinical relevance of blood-based ctDNA analysis: mutation detection and beyond. Br J Cancer. 2021;124(2):345\u201358.","journal-title":"Br J Cancer"},{"issue":"7\u20139","key":"651_CR79","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1080\/15384047.2021.1963166","volume":"22","author":"D Hsiehchen","year":"2021","unstructured":"Hsiehchen D, et\u00a0al. Clinical and biological determinants of circulating tumor DNA detection and prognostication using a next-generation sequencing panel assay. Cancer Biol Ther. 2021;22(7\u20139):455\u201364.","journal-title":"Cancer Biol Ther"},{"key":"651_CR80","doi-asserted-by":"publisher","first-page":"1610103","DOI":"10.3389\/pore.2022.1610103","volume":"28","author":"CT Boniface","year":"2022","unstructured":"Boniface CT, Spellman PT. Blood, toil, and taxoteres: biological determinates of treatment-induce ctDNA dynamics for interpreting tumor response. Pathol Oncol Res. 2022;28:1610103.","journal-title":"Pathol Oncol Res"},{"key":"651_CR81","doi-asserted-by":"crossref","unstructured":"Khier, S. and P.B. Gahan. Hepatic Clearance of Cell-Free DNA: Possible Impact on Early Metastasis Diagnosis. Mol Diagn Ther. 2021.","DOI":"10.1007\/s40291-021-00554-2"},{"issue":"6","key":"651_CR82","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1136\/gut.2010.226092","volume":"60","author":"A Neesse","year":"2011","unstructured":"Neesse A, et\u00a0al. Stromal biology and therapy in pancreatic cancer. Gut. 2011;60(6):861\u20138.","journal-title":"Gut"},{"key":"651_CR83","unstructured":"Bettegowda, C., et\u00a0al., Detection of circulating tumor DNA in early-and late-stage human malignancies. Science translational medicine, 2014. 6(224): p. 224ra24-224ra24."},{"issue":"1","key":"651_CR84","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1002\/path.6019","volume":"259","author":"S Birke\u00e4lv","year":"2023","unstructured":"Birke\u00e4lv S, et\u00a0al. Mutually exclusive genetic interactions and gene essentiality shape the genomic landscape of primary melanoma. J Pathol. 2023;259(1):56\u201368.","journal-title":"J Pathol"},{"key":"651_CR85","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.ejca.2017.05.015","volume":"81","author":"A Valachis","year":"2017","unstructured":"Valachis A, Ullenhag GJ. Discrepancy in BRAF status among patients with metastatic malignant melanoma: A meta-analysis. Eur J Cancer. 2017;81:106\u201315.","journal-title":"Eur J Cancer"},{"issue":"5","key":"651_CR86","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1111\/bjd.12504","volume":"169","author":"H Ekedahl","year":"2013","unstructured":"Ekedahl H, et\u00a0al. The clinical significance of BRAF and NRAS mutations in a clinic-based metastatic melanoma cohort. Br J Dermatol. 2013;169(5):1049\u201355.","journal-title":"Br J Dermatol"},{"issue":"1","key":"651_CR87","first-page":"80","volume":"4","author":"H Shi","year":"2014","unstructured":"Shi H, et\u00a0al. Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. 2014;4(1):80\u201393.","journal-title":"Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy."},{"issue":"47","key":"651_CR88","doi-asserted-by":"publisher","first-page":"77163","DOI":"10.18632\/oncotarget.12848","volume":"7","author":"MI Raaijmakers","year":"2016","unstructured":"Raaijmakers MI, et\u00a0al. Co-existence of BRAF and NRAS driver mutations in the same melanoma cells results in heterogeneity of targeted therapy resistance. Oncotarget. 2016;7(47):77163\u201374.","journal-title":"Oncotarget"},{"issue":"1","key":"651_CR89","doi-asserted-by":"publisher","first-page":"3153","DOI":"10.1038\/s41467-022-30881-9","volume":"13","author":"BM Murphy","year":"2022","unstructured":"Murphy BM, et\u00a0al. Enhanced BRAF engagement by NRAS mutants capable of promoting melanoma initiation. Nat Commun. 2022;13(1):3153.","journal-title":"Nat Commun"},{"issue":"1","key":"651_CR90","doi-asserted-by":"publisher","first-page":"10761","DOI":"10.1038\/s41598-021-89592-8","volume":"11","author":"J Garcia","year":"2021","unstructured":"Garcia J, et\u00a0al. Sensitivity, specificity, and accuracy of a liquid biopsy approach utilizing molecular amplification pools. Sci Rep. 2021;11(1):10761.","journal-title":"Sci Rep"},{"key":"651_CR91","doi-asserted-by":"crossref","unstructured":"Guibert, N. et\u00a0al. Amplicon-based next-generation sequencing of plasma cell-free DNA for detection of driver and resistance mutations in advanced non-small cell lung cancer. Ann Oncol. 2018.","DOI":"10.1093\/annonc\/mdy005"},{"issue":"6","key":"651_CR92","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1001\/jamaoncol.2017.4027","volume":"4","author":"G Torga","year":"2018","unstructured":"Torga G, Pienta KJ. Patient-paired sample congruence between 2 commercial liquid biopsy tests. JAMA Oncol. 2018;4(6):868\u201370.","journal-title":"JAMA Oncol"},{"key":"651_CR93","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.18.00191","volume":"3","author":"D Stetson","year":"2019","unstructured":"Stetson D, et\u00a0al. Orthogonal comparison of four plasma ngs tests with tumor suggests technical factors are a major source of assay discordance. JCO Precis Oncol. 2019;3:1\u20139.","journal-title":"JCO Precis Oncol"},{"issue":"4","key":"651_CR94","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/s40291-021-00534-6","volume":"25","author":"HR Underhill","year":"2021","unstructured":"Underhill HR. Leveraging the fragment length of circulating tumour DNA to Improve molecular profiling of solid tumour malignancies with next-generation sequencing: A pathway to advanced non-invasive diagnostics in precision oncology? Mol Diagn Ther. 2021;25(4):389\u2013408.","journal-title":"Mol Diagn Ther"},{"key":"651_CR95","doi-asserted-by":"crossref","unstructured":"Diefenbach, R.J. et\u00a0al. Hypermethylation of circulating free DNA in cutaneous melanoma. Appl Sci. 2019. 9(23).","DOI":"10.3390\/app9235074"},{"issue":"4","key":"651_CR96","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1007\/s40291-017-0269-9","volume":"21","author":"Q Zeng","year":"2017","unstructured":"Zeng Q, et\u00a0al. Detection of PIK3CA mutations in plasma DNA of colorectal cancer patients by an ultra-sensitive PNA-mediated PCR. Mol Diagn Ther. 2017;21(4):443\u201351.","journal-title":"Mol Diagn Ther"},{"issue":"1","key":"651_CR97","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s40291-019-00442-w","volume":"24","author":"L Sorber","year":"2020","unstructured":"Sorber L, et\u00a0al. Specialized blood collection tubes for liquid biopsy: Improving the pre-analytical conditions. Mol Diagn Ther. 2020;24(1):113\u201324.","journal-title":"Mol Diagn Ther"}],"container-title":["Molecular Diagnosis & Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40291-023-00651-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40291-023-00651-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40291-023-00651-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,19]],"date-time":"2024-10-19T02:37:22Z","timestamp":1729305442000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40291-023-00651-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,26]]},"references-count":97,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["651"],"URL":"https:\/\/doi.org\/10.1007\/s40291-023-00651-4","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2022.09.19.22280131","asserted-by":"object"}]},"ISSN":["1177-1062","1179-2000"],"issn-type":[{"value":"1177-1062","type":"print"},{"value":"1179-2000","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,26]]},"assertion":[{"value":"4 April 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Open Access funding enabled and organized by CAUL and its Member Institutions. This work was financially supported by the Healthier Lives National Science Challenge, Cancer Research Trust NZ, the William Staunton Scholarship Fund, the Maurice Wilkins Centre and the University of Auckland School of Medicine Foundation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The authors have no conflicts of interest that are directly relevant to this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the NZ Health and Disability Ethics Committee, ethical approval number 16\/NTA\/180.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All patients provided written informed consent.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The data that support the findings of this study are available upon reasonable request from the corresponding author.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"CGP, PG, RS, JM and CB initiated the study and contributed to the conception and design. SF contributed to the design of the study, developed molecular protocols, analysis of samples and data, and along with CGP was the primary author of this publication. AL provided research supervision. TS, RS, JM, RM, CJ, BL and GR contributed to the clinical protocol design, patient recruitment, clinical and genomic data collection as well as overall interpretation. TR contributed to statistical analysis. ER contributed to the sequencing panel design. All authors contributed to the revision and approved the final manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}